Abstract
A novel taxane improves progression-free and overall survival of patients with metastatic, hormone-refractory prostate cancer after failure of docetaxel therapy.
| Original language | English |
|---|---|
| Pages (from-to) | 540-542 |
| Number of pages | 3 |
| Journal | Community Oncology |
| Volume | 7 |
| Issue number | 12 |
| State | Published - Dec 2010 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Oncology
- Hematology
Cite this
Cabazitaxel and prednisone as second-line therapy of metastatic, castration-resistant prostate cancer. / Jana, Bagi.
In: Community Oncology, Vol. 7, No. 12, 12.2010, p. 540-542.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Cabazitaxel and prednisone as second-line therapy of metastatic, castration-resistant prostate cancer
AU - Jana, Bagi
PY - 2010/12
Y1 - 2010/12
N2 - A novel taxane improves progression-free and overall survival of patients with metastatic, hormone-refractory prostate cancer after failure of docetaxel therapy.
AB - A novel taxane improves progression-free and overall survival of patients with metastatic, hormone-refractory prostate cancer after failure of docetaxel therapy.
UR - http://www.scopus.com/inward/record.url?scp=78651246898&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=78651246898&partnerID=8YFLogxK
M3 - Article
VL - 7
SP - 540
EP - 542
JO - Community Oncology
JF - Community Oncology
SN - 1548-5315
IS - 12
ER -